Review

Targeting Aggrephagy for the Treatment of Alzheimer’s Disease

Sandeep Malampati 1, Ju-Xian Song 1,2, Benjamin Chun-Kit Tong 1, Anusha Nalluri 1,
Chuan-Bin Yang 1, Ziyi Wang 1, Sravan Gopalkrishnashetty Sreenivasmurthy 1, Zhou Zhu 1,
Jia Liu 1, Chengfu Su 1, Senthilkumar Krishnamoorthi 1, Ashok Iyaswamy 1, King-Ho Cheung 1,
Jia-Hong Lu 3, and Min Li 1,*

1 Mr. and Mrs. Ko Chi Ming Centre for Parkinson’s Disease Research, School of Chinese Medicine,
Hong Kong Baptist University, Hong Kong, China; deepu.pharma08@gmail.com (S.M.);
juxian.song@gmail.com (J.-X.S.); benjamintck@gmail.com (B.C.-K.T.);
anusha.nalluri1111@gmail.com (A.N.); nkyangchb@gmail.com (C.-B.Y.); Wangziyings12@163.com (Z.W.);
sravangs@gmail.com (S.G.S.); zzhou1022@gmail.com (Z.Z.); liuiatheone@hotmail.com (J.L.);
suchengfu@hkbu.edu.hk (C.F.S.); senthilslab@gmail.com (S.K.); ashokenviro@gmail.com (A.I.);
kingho@hkbu.edu.hk (K.-H.C.)

2 Medical College of Acupuncture-Moxibustion and Rehabilitation,
Guangzhou University of Chinese Medicine, Guangzhou 510006, China

3 State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences,
University of Macau, Macao, China; jiahonglu@um.edu.mo

* Correspondence: limin@hkbu.edu.hk

Received: 1 December 2019; Accepted: 26 January 2020; Published: 28 January 2020

Abstract: Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases in older
individuals with specific neuropsychiatric symptoms. It is a proteinopathy, pathologically
characterized by the presence of misfolded protein (Aβ and Tau) aggregates in the brain, causing
progressive dementia. Increasing studies have provided evidence that the defect in protein-
degrading systems, especially the autophagy-lysosome pathway (ALP), plays an important role in
the pathogenesis of AD. Recent studies have demonstrated that AD-associated protein aggregates
can be selectively recognized by some receptors and then be degraded by ALP, a process termed
aggrephagy. In this study, we reviewed the role of aggrephagy in AD development and discussed
the strategy of promoting aggrephagy using small molecules for the treatment of AD.

Keywords: aggrephagy; selective autophagy; Alzheimer’s disease; aggregates

1. Introduction

Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder in the world. It is
clinically characterized by memory dysfunction; it is pathologically characterized by beta-amyloid
(Aβ) and tau toxic aggregates [1] in the cortex and hippocampus of the brain. Senile plaques
composed of fibrillar Aβ and neurofibrillary tangles (NFTs) formed by hyperphosphorylated tau (p-
Tau) proteins are currently considered as the main pathological markers of AD [2,3]. This AD
pathology appears to be associated with the mutated gene inheritance (familial AD) in early-onset
AD or caused by the uncertain genetic or environmental factors (sporadic AD) in the most prevalent
late-onset AD cases [4]. In familial AD mutation, the normal non-amyloidogenic cleavage of amyloid
precursor protein (APP) involving α-secretase and γ-secretase is shifted to the Aβ producing,
abnormal amyloidogenic pathway involving β-secretase and γ-secretase, and the generated Aβ self-
aggregates into oligomers and fibrils [5–7]. Autosomal dominant inheritance of APP gene mutation,
as well as γ-secretase components Presenilin-1 and Presenilin-2 gene mutations are strongly correlated with Aβ pathology [8,9]. According to the amyloid cascade hypothesis, Aβ production and its oligomer formation is the main AD pathological event and it is followed by NFT formation [10]. NFTs are formed due to neuronal microtubule-stabilizing protein tau hyperphosphorylation [11]. The irregular phosphorylation of tau prevents it from stabilizing microtubules and thereby induces it to undergo self-aggregation [12,13]. The impaired degradation of these aggregation-prone proteins leads to cytotoxicity, neuronal atrophy, neurodegeneration, and, ultimately, synaptic impairment and memory deficits [14,15].

How do cells, especially neurons, rid themselves of the aggregation-prone proteins? The ubiquitin-proteasome system (UPS), chaperone-mediated autophagy (CMA), and the autophagy-lysosomal pathway (ALP) are the main cellular processes responsible for this function [16]. UPS and CMA degrade short-lived soluble proteins. Large, long-lived insoluble protein aggregates can only be degraded by macroautophagy (hereafter referred to as autophagy). Autophagy was initially considered to be a bulk degradation system [17]. However, increasing evidence indicates that autophagy can be highly specific, mediated by some receptors which recognize the substrates for degradation [18]. The term aggrephagy was introduced to describe the selective clearance of protein aggregates by autophagy [19]. In this review, we will discuss recent advances in understanding aggrephagy impairment in AD and in purposefully targeting aggrephagy with small molecules as a strategy for the prevention and treatment of AD (Figure 1).

2. Process and Regulation of Aggrephagy

2.1. Aggresome Formation

The selective autophagic clearance of aggregated proteins is called aggrephagy [17]. In proteinopathy, hydrophobic interaction in-between the aggregation-prone proteins lead to the formation of aggregates. In general, the amino acid sequence of a protein determines its post-translational modifications [20]. Post-translational modifications, such as protein folding, not only regulate the protein function but also mask the hydrophobic regions in the newly synthesized protein [20,21]. However, events such as intense protein overexpression, gene missense mutation, incomplete protein synthesis, endoplasmic reticulum stress, and protein folding co-factors shortages may cause unmasking of these hydrophobic protein regions [22]. Intra-protein interaction between the exposed hydrophobic areas results in misfolded proteins. Interaction of exposed hydrophobic regions between multiple misfolded proteins leads to the creation of protein aggregates. Once a protein aggregate is formed, its exposed hydrophobic regions will further recruit misfolded proteins until its hydrophobic regions are covered [23,24]. These aggregates cause impaired neuronal membrane permeability, irregular calcium homeostasis, inflammation, oxidative stress-induced neurotoxicity, and physiological abnormalities [15,25,26]. Healthy neurons can counteract this process by packing misfolded proteins into early aggresomes, which are membrane-free, large insoluble structure located near the nucleus [27]. These early aggresomes are cytotoxic and they are surrounded by intermediate cytoskeleton filaments. In the later stage, aggresomes are processed into non-toxic double-membrane autophagosome and degraded in the lysosome [28–31].

2.2. Aggrephagy Regulation

The pathophysiology of proteinopathy is directly related to detergent-soluble misfolded proteins long term aggregation into devastating detergent-insoluble aggregates [32]. Heat shock proteins (HSPs), constitutive chaperone-mediated autophagy (CMA), and the ubiquitin proteasomal system (UPS) halt the detergent-soluble aggregation-prone protein level elevation [16]. HSP60, HSP70, and HSP90 can bind to misfolded proteins to refold them. They can also neutralize the exposed hydrophobic regions in the misfolded proteins and stop their aggregation process [33]. In the CMA pathway, heat shock cognate protein 70 (HSC70) binds to the KFERQ motif of the misfolded protein and delivers it directly to a lysosome via LAMP2a for degradation (Figure 1) [34]. In UPS and canonical autophagy, the ubiquitination of the aggregates is vital for their degradation [35]. Ubiquitin
contains seven lysine residues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, and Lys63) [36]. These lysine residues covalently bind to the aggregates and form polyubiquitinated chains that can be recognized for degradation [37]. In particular, Lys48-linked polyubiquitinated aggregates are specific for UPS degradation. The aggregates will be delivered to 26S proteasome and undergo ATP-dependent unfolding, followed by proteasome digestion (Figure 1) [38,39]. However, both UPS and CMA pathways are unable to deal with dense aggregates. Besides, UPS and CMA machinery are susceptible to aggregate processing, and an overwhelming protein load will saturate their aggregate-handling ability. In such a case, aggrephagy will be activated and serve as an alternative degradation mechanism [17].

2.3. Role of Aggrephagy Receptors

Sequestosome-1/p62, a neighbor of BRCA1 gene 1 (NBR1), and optineurin are aggrephagy-specific cargo receptors. These aggrephagy receptors act as binding bridges between polyubiquitinated substrates as well as autophagosomal microtubule light chain complex-II (LC3-II) and GABARAP [17]. Ubiquitin-binding domain (UBD) and LC3-interacting motif in both p62 and NBR1 are essential for aggrephagy receptor function. In both p62 and NBR1, UBD located in the C-terminal region specifically recognizes Lys63-linked polyubiquitin substrates and forms complex [40]. Simultaneously, the LC3-interacting motif in p62 and NBR1 promotes the delivery of complexes formed from p62 or NBR1 and polyubiquitinated aggregates to autophagosomes (Figure 1). Among these receptors, p62 is the only essential one for the regulation of substrate ubiquitination, and this ubiquitinated substrates lysosomal digestion. For example, it is suggested that p62 can influence TRAF6 (E3 ubiquitin ligase)-mediated polyubiquitination [41]. Also, p62 recruits a 400 KD autophagy linked FYVE (ALFY) nuclear protein into the cytoplasm for the autophagic degradation of aggregates. ALFY is crucial in facilitating interaction between p62-linked aggregates and autophagosome membrane-bound LC3 [42]. The ALFY C-terminal region has BEACH, FYVE, and WD40 domains, which are crucial to this peptide’s functional role in aggrephagy [43]. In particular, the binding of its WD40 domain to Atg5 is essential for ATG5-ATG12-ATG16L1 E3 ligase complex formation. Binding of its FYVE domain to PtdIns3P enhances phagophore formation, while its BEACH domain binds to the p62-aggregate complex and acts as a scaffold between LC3 in phagophores [44]. Under normal autophagy conditions, p62 and NBR1 aggrephagy receptors facilitate aggregate degradation (Figure 1). It has been demonstrated that under limited autophagy conditions, the impaired clearance of p62 and NBR1 promotes the formation of toxic oligomers and aggregates. These p62 and NBR1 colocalized toxic aggregates incorporate into the toxic aggregates and expand them [45]. Also, when proteasomal aggregate degradation is impaired, tripartite motif-containing 50 (TRIM50) can enhance aggrephagy. TRIM50 is an E3 ubiquitin ligase, and it is reported to increase the aggregation of polyubiquitinated substrates into aggresomes. It enhances aggrephagy by increasing p62 expression and also by influencing HDAC6-mediated misfolded protein retrograde axonal transport when proteasomal aggregates degradation is impaired [46].
Figure 1. Misfolded proteins degradation processes in Alzheimer’s Disease (AD). Ubiquitin-proteasome system (UPS) and chaperone-mediated autophagy (CMA) proteolytic pathways are vulnerable to AD aggregates, and their impairment activates aggrephagy. The misfolded proteins with the KFERQ motif are recognized by HSC70 and recruited directly into lysosome via LAMP2a for degradation in CMA. In UPS the ubiquitinated misfolded proteins are degraded in proteasome. However, in AD, as these constitutive proteolytic pathways are vulnerable to the AD aggregates, aggrephagy is initiated. In aggrephagy, ubiquitinated aggregates, as well as their aggresomes are recognized by the aggrephagy receptors p62, Optineurin (OPTN), and neighbor of BRCA1 gene 1 (NBR1) and recruited eventually into the LC3-II containing double-membranous autophagosome. Further, this autophagosome fuses with the lysosome to form autolysosome and degrades these AD aggregates.

2.4. Role of HDAC6 in Aggrephagy

Misfolded proteins generated in axons and dendrites are retrogradely transported to the lysosome-rich microtubule-organizing center (MTOC). In MTOC, they are packed into aggresomes, and subsequently degraded in the lysosome [47,48]. These functions are regulated by histone deacetylase-6 (HDAC6). HDAC6 is a deacetylating enzyme that is crucial in the microtubule-transport machinery [49]. In aggrephagy, HDAC6 deacetylates α-tubulin, cortactin, and HSP-90 [50]. Also, HDAC6 is actively involved in the sorting of polyubiquitinated misfolded proteins for axonal retrograde transportation that uses Dynein-snapin, a motor-adaptor complex [51]. Many other factors are involved in regulating HDAC6-associated aggrephagy. Protein kinase-2 (CK2) phosphorylates HDAC6 directly and regulates its deacetylation activity [52]. Aggregates polyubiquitinated by TRIM50, TRAF6, and parkin E3 ubiquitin ligases [53,54] are simultaneously deubiquitinated by ataxin-3 to generate diglycine motifs at ubiquitin C-terminuses to form recognition sites for HDAC6. HDAC6 recognizes the diglycine motifs of aggregates through its ubiquitin zinc finger domain (BUZ). Then HDAC6 recruits these aggregates to dynein motor complex through its dynein motor binding domain (DMB). The recruited aggregates are transported via a dynein-snapin axonal microtubule transport system and packed into aggresomes near MTOC (Figure 2) [55]. HDAC6-mediated LC3-II deacetylation is associated with starvation-induced autophagy induction and aggregates degradation [56]. It is found that p62 colocalizes and inhibits HDAC6 deacetylation. As a result, cortactin acetylation is promoted, which is necessary for cytoskeletal F-Actin network...
remodeling. F-Actin network remodeling enables autophagosome maturation and facilitates aggregate clearance [54].

3. Aggrephagy Dysfunction in AD

3.1. Aggresomes in AD

AD pathological proteins Aβ and p-Tau can form aggresomes. Lu et al. showed that cells overexpressing APP Arctic mutation (APP693G) resulted in APP amyloidogenic processing and increased Aβ-42 levels. Using super-resolution microscopy, they found that elevated Aβ-42 monomers progressively assembled into degradation-resistant aggresomes in the perinuclear space [57]. In general, ubiquitin binds to Aβ for proteasomal degradation [58]. Also, these polyubiquitinated chains on Aβ cause thermodynamic instability. As a result, they are not appropriately folded, making this Aβ resistant to proteasomal degradation. Impairment in proper Aβ folding alters their physicochemical properties and enhances Aβ fibrils and plaques formation. Altogether, Aβ is unfolded due to the polyubiquitination, and this unfolded Aβ aggregates into insoluble Aβ fibrils. In aggrephagy, polyubiquitinated Aβ peptides are subjected to autophagic degradation. These polyubiquitinated Aβ fibrils and aggregates selectively bind to UBA domains of p62 and NBR1 to initiate their degradation through aggrephagy [59]. On the other hand, the role of HDAC6 in Aβ aggresome formation is still unclear. Ran-binding protein-9 (RanBP9) levels have been found to be elevated in the AD patient brain [60]. It is proven that RanBP9 increases Aβ secretion by increasing the β-secretase activity [61], and it can also influence aggresome formation by interacting with HDAC6 [62]. However, there is no direct evidence elucidating HDAC6 and RanBP9 inter-relationship in Aβ aggresome formation and its autophagic degradation.

Clinically AD is expressed in the form of extracellular Aβ surrounded by the dystrophic neurites with intracellular NFTs [63]. NFTs are formed due to the aggregation of abnormally hyperphosphorylated tau into paired helical filaments (PHFs) [64]. p-Tau generated at the synapse are retrogradely transported to form aggresomes near the nucleus for lysosomal degradation [65]. It is reported that cells treated with human PHFs can internalize this extracellular tau and form vimentin- and dynein-colocalized aggresomes near perinuclear spaces [27]. When proteasomal aggregates degradation is inhibited, the carboxyl terminus of heat-shock cognate (Hsc)70-interacting protein (CHIP) in association with HSP 70 regulates tau ubiquitination [66]. The ubiquitinated p-Tau is recruited by aggrephagy receptor p62 [65,67]. HDAC6 binds to p62 and promotes the p-Tau and p62 complex retrograde transport to form tau aggresomes [68]. Also, studies reported that HDAC6 responds to the proteostasis stress caused by proteasomal inhibition and re-organizes the cytoskeletal actin network to induce tau aggresome formation [69,70]. Studies reported that ubiquitin carboxy-terminal hydroylase-L1 (UCH-L1) enzyme also influences tau aggresome formation. UCH-L1 is a deubiquitinating enzyme, and it is abundantly expressed in the brain [71]. UCH-L1 inhibition results in tau hyperphosphorylation and also tau microtubule-stabilizing functional loss [72]. Moreover, UCHL1 can modulate HDAC6 activity and affects tau aggresome formation. UCHL1 inhibition reduces the interaction between p-Tau as well as HDAC6 and suppresses tau aggresome formation [73].

3.2. Dysregulation in Aggregates Retrograde Transport in AD

Quick autophagic degradation of AD pathological proteins is necessary for the maintenance of synaptic plasticity [74]. Failure in this dynamic process is one of the main reasons for altered synaptic plasticity and cognitive decline in AD [75]. Alterations in fast axonal transport are observed in different AD Drosophila [76] and mice [77,78] models. Aβ and p-Tau accumulation at synapses impairs synaptic neurotransmission and axonal retrograde transport [79]. Normally, p-Tau peptides produced at the synaptic region are recruited directly or as aggresomes into autophagosomes [65,80], and they are retrogradely transported to neuronal perinuclear space for aggrephagy-mediated lysosomal degradation [68]. Also, p-Tau aggresome formation requires microtubule motor/adaptor proteins dynein/snapin complex-mediated axonal retrograde transport [68]. But in AD, Aβ as well as
tau affect both kinesin and dynein functions, which are necessary for axonal anterograde and retrograde transportation mechanisms, respectively [81–85]. Also, a study reported that Aβ oligomers present in the autophagic vacuole competitively inhibit dynein and snapin coupling and their complex formation. This complex is necessary for the fast axonal transport of aggregates and autophagy vacuoles to the perinuclear space for lysosomal degradation [86]. Impairment in their axonal transportation affects their lysosomal degradation [47]. Moreover, this impairment increases the aggregates level in neuronal axons and synapses. This increase reduces synaptic plasticity and promotes neurodegeneration [79]. Similarly, dynactin-P50, a dynein subunit expression increases with age, whereas dynactin-P50 expression is reduced and colocalized with Aβ plaques in AD patients carrying APOEε3,3 or APOEε4,4 mutation [87]. Also, microtubule anterograde transport protein Kinesin-1 knockout caused axonal transport impairment in APP overexpressed Tg53xTAPP Bret mouse. These mice are observed with elevated Aβ42/Aβ40 ratio, causing autophagy vacuoles accumulation and axonal swelling [88]. Furthermore, these stranded autophagy vacuoles accumulated in axons are filled with AD pathologic proteins, and they fuse with the neuron plasma membrane [89]. This fusion results in membrane expansion, neuronal dystrophy, and neurodegeneration. Autophagy vacuole accumulation in distal end of neurons imposes neuronal autophagy stress in AD [47]. These synaptic autophagy vacuoles and aggregates clearance failure imposes synaptic toxicity resulting in impaired synaptic plasticity and memory dysfunction (Figure 2) [90,91].

CK2, protein phosphatase-1 (PP-1), and glycogen synthase kinase-3β (GSK-3β) kinases are actively involved in the axonal transport mechanism, and their functions in this transport mechanism are impaired in AD [92–94]. Janosine kinase-3 interacting protein-3 (JIP3) knockout in 5xFAD mice aggravates Aβ plaque pathology due to lysosomal accumulation in axons mimicking neuronal dystrophy. In these mice, accumulated lysosomes have increased levels of APP amyloidogenic processing enzymes, BACE1, and PS2 [95]. In another study, neurites associated with Aβ plaques were found to disrupt microtubule structure and elevate the BACE1 level [8]. Elevated BACE1 cleaves the APP present in the accumulated autophagic vacuoles and further raises the Aβ level [96]. Also, loss of nuclear receptor-binding factor-2 (NRBF2), an autophagy gene, results in APP-CTF accumulation and Aβ production [97]. Increased Aβ load in autophagic vacuoles further exacerbates autophagy stress and AD pathology. Aggravated AD pathology ultimately affects communication between neurons, as well as their normal function, and ultimately resulting in neuronal death [8,98].

Figure 2. Fast axonal transport impairment in AD. Impairment in the microtubule-dependent fast axonal transportation of misfolded protein aggregates and autophagy vacuoles from the neuronal distal end to the lysosome rich microtubule-organizing center (MTOC) leads to neuronal dystrophy in AD. Usually, HDAC6 recognizes ubiquitinated AD misfolded proteins p-Tau, Aβ, their aggregates, and autophagy vacuoles. Then they are retrogradely transported by the axonal microtubule motor/adaptor complex dynein/snapin for autophagic degradation in MTOC. However, in AD, retrograde axonal transportation impairment increases neuronal autophagy stress, causing p-Tau and
Aβ aggregates, as well as these aggregates, filled autophagy vacuoles fusion with the plasma membrane resulting in neuronal dystrophy.

3.3. Aggrephagy Receptor Impairment

Nuclear factor (erythroid-derived 2)-like factor (Nrf2) is a leucine zipper family protein. It regulates the expression of aggrephagy receptors p62 and NBR1 [99–103]. Also, it acts against aggregate-induced oxidative stress by increasing the antioxidant response element (ARE) expression. However, Nrf2 expression is found reduced in aged APP/PS1 mouse hippocampus, and due to this reduction, p62 and NBR1 expressions are also reduced [104]. Tripartite motif containing 16 (TRIM16), an E3 ubiquitin ligase regulates Nrf2 ubiquitination and enhances its stability by increasing the autophagic degradation of its negative regulator KEAP1. TRIM16 controls aggrephagy by enhancing the p62-KEAP1-Nrf2 signaling pathway [105]. In this pathway, KEAP1 interacts with Nrf2, and it acts as an adaptor protein for Nrf2 ubiquitination via cullin-3 ubiquitin ligase. Ubiquitinated NRF2 is degraded in proteasomes. But, p62 competitively binds to KEAP1 at the Nrf2 binding region and prevents its interaction with Nrf2. Hence, p62 binding to KEAP1 prevents Nrf2 ubiquitination and its proteasomal degradation [106]. TRIM16 inactivates KEAP1 by increasing its interaction with p62, and p62 facilitates KEAP1 autophagic degradation [105,107]. However, in an AD human brain temporal cortex, the KEAP1-interacting region of p62 is phosphorylated at ser-349 and ser-403 [108]. This abnormal phosphorylation of p62 impairs p62-KEAP1 interaction and results in decreased KEAP1 autophagic degradation. As a result, the KEAP1 level is increased. Activated KEAP1 in the cytoplasm enhances Nrf2 ubiquitination and degradation. The degradation of Nrf2 causes decreased expression of aggrephagy receptors p62, NBR1 and ARE. Reduction in aggrephagy receptors and AREs leads to less aggrephagy and more oxidative stress [105]. Similarly, another aggrephagy receptor NBR1 function may also be impaired due to elevated GSK3 levels in AD [109,110]. It is reported that GSK3 phosphorylates NBR1 at Thr-586 and prevents it from functioning as a polyubiquitinated cargo receptor in muscle cells [109,110]. However, the effect of elevated GSK3 on NBR1 function in AD has not been studied. Taken together, impairment in the expression and function of aggrephagy receptors leads to failure in aggregate degradation and increase of neurotoxicity in AD.

4. Aggrephagy as a Therapeutic Target for the Treatment of AD

4.1. Genetic Approach

Genetic manipulation of pivotal aggrephagy components and transcriptional activation of the autophagy lysosomal pathway (ALP) can improve the clearance of AD pathological aggregates. It is known that aggrephagy is impaired in AD, and HDAC6 promotes the aggrephagy of AD pathological substrates by transporting them to the lysosome rich perinuclear space. However, the HDAC6 expression and its acetylation activity are elevated in the AD patient’s cortex, and the hippocampus [111]. Moreover, in vitro studies demonstrated that HDAC6 downregulation reduces tau cluster formation, Aβ oligomer-induced neuroinflammatory stress and calcium dysregulation [112]. These results are also substantiated by another in vivo study showing that cognitive impairment is restored in HDAC6 knocked down APP/PS1 mice [113]. Hence, inhibition of HDAC6 acetylation activity is an effective therapeutic strategy for neurodegenerative diseases like AD. However, the HDAC6 acetylation inhibitors are anticipated not to affect the ubiquitinated substrates recognition ability of HDAC6 [114]. It is observed that the level of sarkosyl-insoluble tau is inversely related to the expression level of p-Tau ubiquitinating enzyme CHIP in JNPL3, a tau transgenic mice model. In JNPL3 mice, the sarkosyl-insoluble tau level in the cerebellum is less in comparison with the spinal cord region due to more CHIP expression in the cerebellum than the spinal cord. Moreover, in CHIP knockout mice, detergent-insoluble tau levels were elevated without altering the total tau level [115]. These results indicate that enhancing CHIP expression may promote pathological tau aggrephagy. Overexpression of the aggrephagy receptor p62 in APP/PS1 mice can improve cognitive dysfunction and reduce Aβ plaques level by enhancing Aβ autophagic degradation [116]. Also, the
p62 chaperone activity promotes p-Tau solubility thus preventing detergent-insoluble NFT formation, because in the p62 knockout mice brains, Lys63-linked tau aggregates appear, and they are causally related to neurodegeneration and memory loss in these mice [117]. As Nrf2 regulates p62 and NBR1 expression, Nrf2 deficiency has been demonstrated to aggravate AD pathological symptoms [100,118], whereas its overexpression has alleviated both Aβ and p-Tau pathology [119,120]. Transcription factor EB (TFEB) is a master regulator of lysosomal biogenesis, and it also promotes aggrephagy. Much evidence indicates that TFEB overexpression causes profound enhancement of autophagy and induces autophagic clearance of AD aggregates [121–124]. TFEB is a self-transcription regulatory protein [125,126], and it also induces the expression of its gene promoter-peroxisome proliferator-activated receptor gamma co-activator1-α (PPARGC1α) [127]. Agents inducing PPARGC1α expression can reduce the AD aggregate level by activating TFEB and can also restore mitochondrial dysfunction [128,129]. Currently, we are working on small molecules that enhance autophagy lysosomal biogenesis by inducing the TFEB nuclear translocation. Our results indicate that TFEB activators have an excellent effect on reducing AD pathological aggregates as well as restoring cognitive impairment in mice models of AD (Figure 3) [130,131].

4.2. Lysosomes Functional Restoration with Nanotechnology

Lysosomal digestion of autophagy substrates is necessary for the survival of mature neurons [132]. Lysosomal hydrolase (e.g., cathepsin) activity and proteolysis indeed require optimal acidic pH [133]. In AD, presenilin-1 mutations and elevated CTFβ peptide levels impair lysosomal acidification and cathepsin activity, causing a massive pileup of autophagic vesicles with undigested autophagy substrates in neurons [134,135]. Presenilin-1 functional loss due to its mutation impairs the V-ATPase function, which leads to altered lysosomal Ca²⁺ homeostasis and results in defective lysosomal acidification and cathepsin D activity [136]. Also, amyloidogenic APP cleavage product CTFβ shifts lysosomal pH towards alkalinity and reduce cathepsin D activity [135]. These lysosome-related AD pathogenic events can be prevented with acidic nanoparticles. Studies show that these acidic nanoparticles accumulated in lysosomes and show prolonged lysosome functional restoration [137,138]. Specifically, in AD experimental models, treatment with poly-(dl-lactide-co-glycolide)-based acidic nanoparticles can reacidify lysosomes and restore cathepsin activity and autophagy function [135,136].

Figure 3. Process and regulation of aggrephagy in AD. mTORC1 holds Transcription factor EB (TFEB) on the lysosome membrane in phosphorylated form (p-TFEB). Aggrephagy is induced by mTORC1 inhibition or mTORC1 dependent/independent pathways that lead to TFEB activation, i.e., TFEB dephosphorylation. Dephosphorylated TFEB translocates into the nucleus, enhances CLEAR genes
transcription, and promotes autophagy and lysosomal biogenesis. In AD, ubiquitinated monomeric Aβ and p-Tau peptides form misfolded proteins. These polyubiquitinated misfolded proteins are recognized by aggrephagy receptors and recruited into the LC3-II containing phagophore or autophagosome, which transforms into autolysosome after fusion with the lysosome and degrades AD pathological aggregates. Lysosome acidification failure due to PS1) mutation or elevated CTFβ levels can be treated with lysosomes targeted acidic nanoparticles.

4.3. Small Molecule Aggrephagy Enhancers on AD Models

Small molecules that can (1) penetrate the brain, (2) induce aggregate clearance, (3) restore the obstructed axonal transport, as well as autophagy mechanism (4), ameliorate synaptic plasticity and (5) enhance cognitive function are invaluable for clinical AD therapy. Few small molecules have been reported to induce aggrephagy and reduce AD pathological aggregates by inhibiting the mammalian target of rapamycin (mTOR), as well as by the activation of TFEB (Table 1).

4.3.1. mTOR-Inhibiting Aggrephagy Inducers

mTOR regulates protein synthesis, cell proliferation, and growth. Depending on the availability of nutrition, it regulates the phosphorylation of its downstream targets P70S6K and 4EBP1 protein [139]. Growth factors and amino acids induce PtdIns3 kinase activity, phosphorylate AKT, and activate mTOR. The deficiency of these substances causes AMPK to phosphorylate the regulatory-associated protein of mTOR (RAPTOR) and generate binding sites for the 14-3-3 complexes that inhibit mTOR activity [140]. Under cell growth-promoting conditions, mTOR phosphorylates unc-51-like kinase 1 (ULK1), whereas, under conditions not favoring cell growth, ULK1 will be dephosphorylated and initiate autophagy [141]. The mTOR activity can be inhibited directly with rapamycin and torin1, or indirectly with wortmannin [142] and amino acid starvation [56,141,143–145]. Among these, rapamycin is a natural macrolide derivative reported to reduce AD pathological aggregates. Rapamycin treatment in AD mice has alleviated Aβ burden, improved memory dysfunction, and rescued cerebral amyloid angiopathy [144,146]. Rapamycin, as well as its prodrug form Temsirolimus [147] shows potent AD therapeutic effect in reducing p-Tau aggregates in P301S mice [148,149]. Polyphenol curcumin is a potent PI3K and mTOR inhibitor reported to alleviate AD pathology. Curcumin has restored spatial memory by inducing autophagic degradation of Aβ aggregates in APP/PS1 mice [150]. Curcumin has been extensively studied, and it is well understood to be an anti-AD drug. However, curcumin’s poor brain bioavailability prevents its clinical applications in AD [151–157]. Secoiridoid polyphenol oleuropein aglycone induces autophagy by inhibiting mTOR, and it activates AMPK by releasing Ca2+ from sarcoplasmic reticulum stores [158]. Oleuropein aglycone treatment in TgCRND8 mice has significantly reduced Aβ plaque density and restored synaptic plasticity by activating autophagy in a 12 month-old TgCRND8 mice model [159,160]. Methylene blue can induce autophagy similar to rapamycin and reduce the soluble and insoluble tau aggregates in the JNPL3 tau mice model [161]. However, in clinical trials, methylene blue appears to reduce the tau fibrils only while it increases granular tau oligomer levels [162].

4.3.2. TFEB-Activating Aggrephagy Inducers

mTOR is considered to be one of the master regulators of protein synthesis. Aggrephagy inducers acting independently of mTOR inhibition will not alter protein synthesis. mTOR-independent TFEB activators and aggrephagy inducers have gained much attention recently. Under nutrient-rich conditions, mTOR inactivates autophagy-lysosomal biogenesis gene master regulator TFEB by phosphorylating it at ser-142 and ser-211 sites. TFEB phosphorylation, particularly at ser-211, allows 14-3-3 to bind to p-TFEB resulting in its subcellular localization [163,164]. However, under the starvation condition, TFEB is dephosphorylated and activated. Dephosphorylated TFEB can translocate into the nucleus and induce the transcription of the coordinated lysosomal expression and regulation (CLEAR) gene network. CLEAR gene encodes for the proteins necessary for the formation of autophagosomes, lysosomes, and factors involved in autolysosome formation [165–168]. Few compounds can promote TFEB mediated autophagy and lysosomal biogenesis to reduce the AD
pathological aggregates without inhibiting mTOR activity. The natural disaccharide trehalose enhances TFEB nuclear translocation by inducing limited lysosomal membrane enlargement. It activates protein phosphatase-3 CB (PP3CB), calcineurin, and translocates TFEB into the nucleus, independent of inhibiting mTOR activity [169–174]. Trehalose treatment enhances the plaque clearance in APP/PS1 mice, and it reduces the tangle formation in P301S mice, again, independent of mTOR [170,171,173]. Ouabain is an mTOR and Na+/K+-ATPase inhibitor. It activates TFEB, reduces p-Tau aggregates, and restores cognitive deficits in P301L mice [175,176]. Cardiac glycoside-ingenol derivative Hep14 enhances the TFEB mediated ALP independent of mTOR inhibition. It promotes TFEB mediated ALP by activating PKC (both PKCα and PKCδ) as well as by inhibiting GSK3β. Hep14 induces TFEB nuclear translocation and reduces the plaques in APP/PS1 mice [177]. 5xFAD mice treatment with aspirin and cinnamic acid activates TFEB gene promotor PPARGC1α and increased TFEB expression level. Elevated TFEB promotes lysosomal biogenesis and reduces Aβ plaque burden [178,179].
Table 1. Aggrephagy enhancers for the treatment of AD.

| Compound                  | Mode of Action | Animal Model     | Dose/Route       | Result                                      | Reference          |
|---------------------------|----------------|------------------|-------------------|---------------------------------------------|--------------------|
| Curcumin                  | mTOR inhibition| 1. APP/PS1       | 1. 1000 ppm/P.O.  | ↓ Aβ plaques, ↑ Memory                      | [130,150]          |
| Rapamycin                 | mTOR inhibition| 1. PDAPP mice    | 1. 2.24 mg/kg/P.O.| ↓ Aβ plaques, ↑ Memory                      | [144,146,180]      |
|                           |                | 2. hAPP (J20) mice | 2. 2.24 mg/kg/P.O.| ↓ Cerebral amyloid angiopathy, ↑ Memory     |                    |
|                           |                | 3. P301S mice    | 3. 15 mg/kg/I.P.  | ↑ Sarkosyl insoluble tau                    | [148,181]          |
| Temsirolimus              | mTOR inhibition| 1. P301S mice    | 1. 20 mg/kg/I.P.  | ↓ Sarkosyl insoluble tau, ↑ Memory          |                    |
| Oleuropein                | AMPK activation, mTOR inhibition| 1. TgCRND8 mice | 1. 50 mg/kg/P.O.  | ↓ Aβ plaques, ↑ Memory                      | [159]              |
| Methylene blue            | mTOR inhibition| 1. JNPL3 mice    | 1. 0.02 mg/kg/P.O.| ↑ Sarkosyl insoluble tau                    | [161]              |
| Ouabain                   | mTOR inhibition, TFEB activation| 1. P301L mice  | 1. 1.5 µgm/kg/I.P.| ↑ Sarkosyl insoluble tau, ↑ Memory          |                    |
| Trehalose                 | TFEB activation| 1. P301S mice    | 1. 2% Trehalose in drinking water | ↑ Sarkosyl insoluble tau, ↑ Motor function | [170,173,174]      |
|                           |                | 2. APP/PS1 mice  | 2. 5 µL injected into brain lateral ventricles | ↑ Aβ deposits, ↑ Memory |                      |
| Pseudoginsenoside- F11 (PF-11) | TFEB activation| 1. SAMP8 mice    | 1. 32 mg/kg/P.O.  | ↓ Aβ plaques, ↑ Memory                      | [182,183]          |
| Hep-14                    | TFEB activation| 1. APP/PS1 mice  | 1. 5 mg/kg/I.P.  | ↓ Aβ plaques                                | [177]              |
| Aspirin                   | PPARα mediated TFEB activation| 1. 5xFAD mice    | 1. 2 mg/kg/P.O.  | ↓ Aβ plaques                                | [179]              |
| Cinnamic acid             | PPARα mediated TFEB activation| 1. 5xFAD mice    | 1. 100 mg/kg/P.O. | ↓ Aβ plaques, ↑ Memory, ↑ Open field exploration | [178]              |

P.O: Oral route; I.P: Intraperitoneal route; PPM: parts per million.
5. Conclusion and Future Direction

AD is a type of proteinopathy. It is characterized by progressive accumulation of aberrant Abeta and p-Tau proteins aggregation in the brain, resulting in memory deficits and neurodegeneration. In AD, specific degradation of these aggregates, i.e., aggrephagy, is impaired due to altered substrate recognition, defects in axonal transport mechanism, and failure in lysosome acidification. The impaired aggrephagy process can be restored with aggrephagy enhancers. However, developing aggrephagy enhancers is a challenge because we still do not fully understand the aggrephagy mechanism in AD. For instance, the role of HDAC6 in Aβ and p-Tau aggresome formation, as well as their retrograde transport, and lysosomal degradation is still not clear. Molecular targets that can activate aggrephagy specifically need to be identified. The clearance of the conjugated aggrephagy receptor and aggregates complex is necessary to halt AD progression. In preclinical studies, small molecules targeted to promote ALP by inhibiting mTORC1 or by inducing TFEB nuclear translocation are efficacious in reducing AD aggregates as well as in alleviating memory dysfunction.

In a multifactorial disease like AD, translating clinical AD pathology into an experimental model is challenging. Currently, age-dependent AD transgenic mice models cannot accurately reproduce the clinical pathology of human AD [184,185]. Hence, in the development of an efficient anti-AD candidate to overcome the pre-clinical limitations, multiple transgenic mouse models with different disease phenotypes should be employed. Nevertheless, the clinical failure of aggrephagy inducer methylene blue highlights the importance of careful pre-clinical examination of future aggrephagy-enhancing compounds [162]. With proposed therapeutic agents, screening can eliminate off-target activation and validate their physiological relevance to alleviate the disease. Despite the drawbacks and limitations, developing aggrephagy inducers to alleviate AD pathology remains a promising strategy for improving AD therapy.

Author contributions: S.M., J.-X.S. Conceptualized the study; M.L.; S.M., J.-X.S., C.-B.Y., A.N., Z.W., S.G.S., Z.Z., S.K., J.Y., C.S., and A.I. prepared the manuscript. S.M., J.-X.S., M.L., J.-H.L., B.C.-K.T., and K.-H.C., revised and edited the manuscript. M.L. provided funding. All authors have read and agreed to the published version of the manuscript.

Funding: This work is supported by the National Natural Science Foundation of China (NSFC/81773926, NSFC/81703487), Hong Kong General Research Fund (HKBU121006/18, HKBU121014/17), The Hong Kong Health and Medical Fund (HMRF15163481, HMRF14150811), and Hong Kong Baptist University Research Fund (HKBU/RC-IRCs/17-18/03, HKBU/RC-IRMS/15-16/04, FRGII/17-18/021, and FRGII/16-17/018) to Min Li.

Acknowledgments: We would like to thank Martha Dahlen for the English editing of this manuscript.

Conflicts of Interest: Authors declare no conflict of interest.

References
1. Kelley, B.J.; Petersen, R.C. Alzheimer’s disease and mild cognitive impairment. *Neurol. Clin.* 2007, 25, 577–609, doi:10.1016/j.ncl.2007.03.008.
2. Thinakaran, G.; Koo, E.H. Amyloid precursor protein trafficking, processing, and function. *J. Biol. Chem.* 2008, 283, 29615–29619, doi:10.1074/jbc.R800019200.
3. Schindowski, K.; Bretteville, A.; Leroy, K.; Bégard, S.; Brion, J.P.; Hamdane, M.; Buée, L. Alzheimer’s Disease-Like Tau Neuropathology Leads to Memory Deficits and Loss of Functional Synapses in a Novel Mutated Tau Transgenic Mouse without Any Motor Deficits. *Am. J. Pathol.* 2006, 169, 599–616, doi:10.2353/ajpath.2006.060002.
4. Dorszewska, J.; Prendecki, M.; Oczkowska, A.; Dezor, M.; Kozubski, W. Molecular Basis of Familial and Sporadic Alzheimer’s Disease. *Curr. Alzheimer. Res.* 2016, 13, 952–963, doi:10.2174/1567205013666160314150501.
5. Zhang, Y.; Lyubchenko, Y.L. The structure of misfolded amyloidogenic dimers: Computational analysis of force spectroscopy data. *Biophys. J.* 2014, 107, 2903–2910, doi:10.1016/j.bpj.2014.10.053.
6. Vassar, R. BACE1: The beta-secretase enzyme in Alzheimer’s disease. *J. Mol. Neurosci.* 2004, 23, 105–114, doi:10.1385/jmn:23:1-2:105.
7. Iwatsubo, T. The gamma-secretase complex: Machinery for intramembrane proteolysis. *Curr. Opin. Neurobiol.* **2004**, *14*, 379–383, doi:10.1016/j.conb.2004.05.010.

8. Sadleir, K.R.; Kandalepas, P.C.; Buggia-Prevot, V.; Nicholson, D.A.; Thinakaran, G.; Vassar, R. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Abeta generation in Alzheimer’s disease. *Acta Neuropathol.* **2016**, *132*, 235–256, doi:10.1007/s00401-016-1558-9.

9. Zhang, X.; Li, Y.; Xu, H.; Zhang, Y.W. The gamma-secretase complex: From structure to function. *Front. Cell Neurosci.* **2015**, *8*, 427, doi:10.3389/fncel.2014.00427.

10. Ricciarelli, R.; Fedele, E. The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind. *Curr. Neuropharmacol.* **2017**, *15*, 926–935, doi:10.2174/1570159x15666170116143743.

11. Cummings, J.; Lee, G.; Ritter, A.; Sabbagh, M.; Zhong, K. Alzheimer’s disease drug development pipeline: 2019. *Alzheimers Dement.* **2019**, *5*, 272–293, doi:10.1016/j.trci.2019.05.008.

12. Perl, D.P. Neuropathology of Alzheimer’s disease. *Mt. Sinai J. Med.* **2010**, *77*, 32–42, doi:10.1002/msj.20157.

13. Lim, S.; Haque, M.M.; Kim, D.; Kim, D.J.; Kim, Y.K. Cell-based Models to Investigate Tau Aggregation. *Comput. Struct. Biotechnol. J.* **2014**, *12*, 7–13, doi:10.1016/j.csbj.2014.09.011.

14. Cleary, J.P.; Walsh, D.M.; Hofmeister, J.J.; Shankar, G.M.; Kuskowski, M.A.; Selkoe, D.J.; Ashe, K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. *Nat. Neurosci.* **2005**, *8*, 79–84, doi:10.1038/nn1372.

15. Shankar, G.M.; Li, S.; Mehta, T.H.; Garcia-Munoz, A.; Shepardson, N.E.; Smith, I.; Brett, F.M.; Farrell, M.A.; Rowan, M.J.; Lemere, C.A., et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. *Nat. Med.* **2008**, *14*, 837–842, doi:10.1038/nm1782.

16. Ciechanover, A. Intracellular protein degradation: From a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. *Best Pr. Res. Clín. Haematol.* **2017**, *30*, 341–355, doi:10.1016/j.beha.2017.09.001.

17. Gatica, D.; Lahiri, V.; Klionsky, D.J. Cargo Recognition and Degradation by Selective Autophagy. *Nat. Cell Biol.* **2018**, *20*, 233–242, doi:10.1038/s41556-018-0037-z.

18. Koga, H.; Cuervo, A.M. Chaperone-mediated autophagy dysfunction in the pathogenesis of neurodegeneration. *Neurobiol. Dis.* **2011**, *43*, 29–37, doi:10.1016/j.nbd.2010.07.006.

19. Overbye, A.; Fensrud, M.; Seglen, P.O. Proteomic analysis of membrane-associated proteins from rat liver autophagosomes. *Autophagy* **2007**, *3*, 300–322, doi:10.4161/auto.3.4.3910.

20. Barber, K.W.; Rinehart, J. The ABCs of PTMs. *Nat. Chem. Biol.* **2018**, *14*, 188–192, doi:10.1038/nchembio.2572.

21. Schroder, M.; Kaufman, R.J. The mammalian unfolded protein response. *Annu. Rev. Biochem.* **2005**, *74*, 739–789, doi:10.1146/annurev.biochem.73.111303.074134.

22. Goldberg, A.L. Protein degradation and protection against misfolded or damaged proteins. *Nature* **2003**, *426*, 895–899, doi:10.1038/nature02263.

23. Basso, M.; Samengo, G.; Nardo, G.; Massignan, T.; D’Alejandro, G.; Tartari, S.; Cantoni, L.; Marino, M.; Cheroni, C.; De Biasi, S., et al. Characterization of detergent-insoluble proteins in ALS indicates a causal link between nitrative stress and aggregation in pathogenesis. *PLoS ONE* **2009**, *4*, e8130, doi:10.1371/journal.pone.0008130.

24. Nam, W.H.; Choi, Y.P. In vitro generation of tau aggregates conformationally distinct from parent tau seeds of Alzheimer’s brain. *Prion* **2018**, *13*, 1–12, doi:10.1080/19336896.2018.1545524.

25. De, S.; Wirthensohn, D.C.; Flagmeier, P.; Hughes, C.; Aprile, F.A.; Ruggeri, F.S.; Whiten, D.R.; Emin, D.; Xia, Z.; Varela, J.A., et al. Different soluble aggregates of Abeta42 can give rise to cellular toxicity through different mechanisms. *Nat. Commun.* **2019**, *10*, 1541, doi:10.1038/s41467-019-09477-3.

26. Fusco, G.; Chen, S.W.; Williamson, P.T.F.; Cascella, R.; Perni, M.; Jarvis, J.A.; Cecchi, C.; Vendruscolo, M.; Chiti, F.; Crema, N., et al. Structural basis of membrane disruption and cellular toxicity by alpha-synuclein oligomers. *Science* **2017**, *358*, 1440–1443, doi:10.1126/science.aan6160.

27. Santa-Maria, I.; Varghese, M.; Kieszak-Reding, H.; Dzhun, A.; Wang, J.; Pasinetti, G.M. Paired helical filaments from Alzheimer disease brain induce intracellular accumulation of Tau protein in aggresomes. *J. Biol. Chem.* **2012**, *287*, 20522–20533, doi:10.1074/jbc.M111.325279.

28. Nassar, M.; Samaha, H.; Gabriel, M.; Yehia, M.; Taha, H.; Salem, S.; Shaaban, K.; Omar, M.; Ahmed, N.; El-Naggar, S. LC3A Silencing Hinders Aggresome Vimentin Cage Clearance in Primary Choroid Plexus Carcinoma. *Sci. Rep.* **2017**, *7*, 8022, doi:10.1038/s41598-017-07403-5.
29. Bardag-Gorce, F.; Makalinao, A.; Meepe, I.; Hoft, R.H.; Cortez, D.; Oliva, J.; Laporte, A.; Stark, J.; Gorce, A.; Di Lorenzo, M., et al. Corneal keratin aggresome (CKAGG) formation and clearance by proteasome activation. *Helitogrypsis 2018*, 4, e01012, doi:10.1016/j.heliyon.2018.e01012.

30. Iwata, A.; Christianson, J.C.; Bucci, M.; Ellerby, L.M.; Nukina, N.; Forno, L.S.; Kopito, R.R. Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. *Proc. Natl. Acad. Sci. 2005*, 102, 13135–13140, doi:10.1073/pnas.0505801102.

31. Bucciantini, M.; Giannoni, E.; Chiti, F.; Baroni, F.; Formigli, L.; Zurdo, J.; Taddei, N.; Ramponi, G.; Dobson, C.M.; Stefani, M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. *Nature 2002*, 416, 507–511, doi:10.1038/416507a.

32. Sarkar, S.; Chigurupati, S.; Raymick, J.; Mann, D.; Bowyer, J.F.; Schmitt, T.; Beger, R.D.; Hanig, J.P.; Schmued, L.C.; Paule, M.G. Neuroprotective effect of the chemical chaperone trehalose in a chronic MPTP-induced Parkinson’s disease mouse model. *Neurotoxicology 2014*, 44, 250–262, doi:10.1016/j.neuro.2014.07.006.

33. Mogk, A.; Buka, B. Role of sHsps in organizing cytosolic protein aggregation and disaggregation. *Cell Stress Chaperones 2017*, 22, 493–502, doi:10.1007/s12192-017-0762-4.

34. Ungelenk, S.; Moayed, F.; Ho, C.T.; Grousl, T.; Scharf, A.; Mashaghi, A.; Tans, S.; Mayer, M.P.; Mogk, A.; Buka, B. Small heat shock proteins sequester misfolding proteins in native-like conformation for cellular protection and efficient refolding, *Nat. Commun. 2016*, 7, 13673, doi:10.1038/ncomms13673.

35. Grumati, P.; Dikic, I. Ubiquitin signaling and autophagy. *J. Biol. Chem. 2017*, 293, 5404–5413, doi:10.1074/jbc.T117000117.

36. Peng, J.; Schwartz, D.; Elias, J.E.; Thoreen, C.C.; Cheng, D.; Marsischky, G.; Roelofs, J.; Finley, D.; Gygi, S.P. A proteomics approach to understanding protein ubiquitination. *Nat. Biotechnol. 2003*, 21, 921–926, doi:10.1038/nbt849.

37. Ikeda, F.; Dikic, I. Atypical ubiquitin chains: New molecular signals. Protein Modifications: Beyond the Usual Suspects’ review series. *EMBO Rep. 2008*, 9, 536–542, doi:10.1038/embor.2008.93.

38. Collins, G.A.; Goldberg, A.L. The Logic of the 26S Proteasome. *Cell 2017*, 169, 792–806, doi:10.1016/j.cell.2017.04.023.

39. Finley, D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. *Annu. Rev. Biochem. 2009*, 78, 477–513, doi:10.1146/annurev.biochem.78.015010.101607.

40. Shi, C.S.; Kehrl, J.H. TRAF6 and A20 regulate lysine 63-linked ubiquitination of Beclin-1 to control TLR4-induced autophagy. *Sci. Signal. 2010*, 3, ra42, doi:10.1126/scisignal.2000751.

41. Wooten, M.W.; Geetha, T.; Seibenhener, M.L.; Babu, J.R.; Diaz-Meco, M.T.; Moscat, J. The p62 scaffold regulates nerve growth factor-induced NF-kappaB activation by influencing TRAF6 polyubiquitination. *J. Biol. Chem. 2005*, 280, 35625–35629, doi:10.1074/jbc.C502372200.

42. Lystad, A.H.; Ichimura, Y.; Takagi, K.; Yang, Y.; Pankiv, S.; Kanegae, Y.; Kageyama, S.; Suzuki, M.; Saito, I.; Mizushima, T., et al. Structural determinants in GABARAP required for the selective binding and recruitment of ALFY to LC3B-positive structures. *EMBO Rep. 2014*, 15, 557–565, doi:10.1002/embr.201338003.

43. Isakson, P.; Holland, P.; Simonsen, A. The role of ALFY in selective autophagy. *Cell Death Differ. 2013*, 20, 12–20, doi:10.1038/cdd.2012.66.

44. Filimonenko, M.; Isakson, P.; Finley, K.D.; Anderson, M.; Jeong, H.; Melia, T.J.; Bartlett, B.J.; Myers, K.M.; Birkeland, H.C.; Lamark, T., et al. The selective macroautophagic degradation of aggregated proteins requires the PSIP-binding protein Alfy. *Mol. Cell. 2010*, 38, 265–279, doi:10.1016/j.molcel.2010.04.007.

45. Kirkin, V.; Lamark, T.; Johansen, T.; Dikic, I. NBR1 cooperates with p62 in selective autophagy of ubiquitinated targets. *Autophagy 2009*, 5, 732–733, doi:10.4161/auto.5.5.8566.

46. Fusco, C.; Micale, L.; Egorov, M.; Monti, M.; D’Addetta, E.V.; Angello, B.; Cozzolino, F.; Calagni, A.; Fontana, A.; Polischuk, R.S., et al. The E3-ubiquitin ligase TRIM50 interacts with HADAC6 and p62, and promotes the sequestration and clearance of ubiquitinated proteins into the aggresome. *PLoS ONE 2012*, 7, e40440, doi:10.1371/journal.pone.0040440.

47. Tammineni, P.; Ye, X.; Feng, T.; Alkal, D.; Cai, Q. Impaired retrograde transport of axonal autophagosomes contributes to autophagic stress in Alzheimer’s disease neurons. *eLife 2017*, 6, doi:10.7554/eLife.21776.

48. Cristofani, R.; Crippa, V.; Rusmini, P.; Cicardi, M.E.; Meroni, M.; Licata, N.V.; Sala, G.; Giorgetti, E.; Grunseich, C.; Galbiati, M., et al. Inhibition of retrograde transport modulates misfolded protein
accumulation and clearance in motoneuron diseases. *Autophagy* 2017, 13, 1280–1303, doi:10.1007/s13238-017-0989-5.

49. Iwata, A.; Riley, B.E.; Johnston, J.A.; Kopito, R.R. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. *J. Biol. Chem.* 2005, 280, 40282–40292, doi:10.1074/jbc.M508786200.

50. Li, Y.; Shin, D.; Kwon, S.H. Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. *FERS J.* 2012, 280, 775–793, doi:10.1111/febs.12079.

51. Kawaguchi, Y.; Kovacs, J.J.; McLaurin, A.; Vance, J.M.; Ito, A.; Yao, T.P. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. *Cell* 2003, 115, 727–738, doi:10.1016/s0092-8674(03)00939-5.

52. Watabe, M.; Nakaki, T. Protein kinase CK2 regulates the formation and clearance of aggresomes in response to stress. *J. Cell Sci.* 2011, 124, 1519–1532, doi:10.1242/jcs.081778.

53. Olzmann, J.A.; Li, L.; Chudaev, M.V.; Chen, J.; Perez, F.A.; Palmiter, R.D.; Chin, L.S. Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6. *J. Cell Biol.* 2007, 178, 1025–1038, doi:10.1083/jcb.200611128.

54. Yan, J.; Seibenhenner, M.L.; Calderilla-Barbosa, L.; Diaz-Meco, M.T.; Moscat, J.; Jiang, J.; Wooten, M.W.; Wooten, M.C. SQSTM1/p62 interacts with HDAC6 and regulates deacetylase activity. *PLoS ONE* 2013, 8, e76016, doi:10.1371/journal.pone.0076016.

55. Ouyang, H.; Ali, Y.O.; Ravichandran, M.; Dong, A.; Qiu, W.; MacKenzie, F.; Dhe-Paganon, S.; Arrowsmith, C.H.; Zhai, R.G. Protein aggregates are recruited to aggresome by histone deacetylase 6 via unanchored ubiquitin C termini. *J. Biol. Chem.* 2011, 286, 2317–2327, doi:10.1074/jbc.M111.272730.

56. Liu, K.P.; Zhou, D.; Ouyang, D.Y.; Xu, L.H.; Wang, Y.; Wang, L.X.; Pan, H.; He, X.H. LC3B-II deacetylation by histone deacetylase 6 is involved in serum-starvation-induced autophagic degradation. *Biochem. Biophys. Res. Commun.* 2013, 441, 970–975, doi:10.1016/j.bbrc.2013.11.007.

57. Lu, M.; Williamson, N.; Mishra, A.; Michel, C.H.; Kaminski, C.F.; Tunnacliffe, A.; Kaminski Schierle, G.S. Structural progression of amyloid-beta Arctic mutant aggregation in cells revealed by multiparametric imaging. *J. Biol. Chem.* 2018, 294, 1478–1487, doi:10.1074/jbc.RA118.004511.

58. Hong, L.; Huang, H.C.; Jiang, Z.F. Relationship between amyloid-beta and the ubiquitin-proteasome system in Alzheimer’s disease. *Neural. Res.* 2014, 36, 276–282, doi:10.1179/1743132813y.0000000288.

59. Morimoto, D.; Walinda, E.; Fukada, H.; Sou, Y.S.; Kageyama, S.; Hoshino, M.; Fujii, T.; Tsuchiya, H.; Saeki, Y.; Arita, K., et al. The unexpected role of polyubiquitin chains in the formation of fibrillar aggregates. *Nat. Commun.* 2015, 6, 6116, doi:10.1038/ncomms7116.

60. Lakshmana, M.K.; Chung, J.Y.; Wickramarachchi, S.; Tak, E.; Bianchi, E.; Koo, E.H.; Kang, D.E. A fragment of the scaffolding protein RanBP9 is increased in Alzheimer’s disease brains and strongly potentiates amyloid-beta peptide generation. *FASEB J.* 2009, 24, 119–127, doi:10.1096/fj.09-136457.

61. Lakshmana, M.K.; Yoon, I.S.; Chen, E.; Bianchi, E.; Koo, E.H.; Kang, D.E. Novel role of RanBP9 in BACE1 processing of amyloid precursor protein and amyloid beta peptide generation. *J. Biol. Chem.* 2009, 284, 11863–11872, doi:10.1074/jbc.M807345200.

62. Salemi, L.M.; Almawi, A.W.; Lefebvre, K.J.; Schild-Pouleur, C. Aggresome formation is regulated by RanBP4 through an interaction with HDAC6. *Biol. Open* 2014, 3, 418–430, doi:10.1242/bio.20147021.

63. Iqbal, K.; Alonso, A.C.; Gong, C.X.; Khatoon, S.; Pei, J.J.; Wang, J.Z.; Grundke-Iqbal, I. Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles. *J. Neural. Transm. Suppl.* 1998, 53, 169–180, doi:10.1007/978-3-7091-6467-9_15.

64. Brunden, K.R.; Trojanowski, J.Q.; Lee, V.M. Advances in tau-focused drug discovery for Alzheimer’s disease and related tauopathies. *Nat. Rev. Drug Discov.* 2009, 8, 783–793, doi:10.1038/nrd2959.

65. Guo, J.L.; Buist, A.; Soares, A.; Callaerts, K.; Calafate, S.; Stevenaert, F.; Daniels, J.P.; Zoll, B.E.; Crowe, A.; Brunden, K.R., et al. The Dynamics and Turnover of Tau Aggregates in Cultured Cells: INSIGHTS INTO THERAPIES FOR TAUOPATHIES. *J. Biol. Chem.* 2016, 291, 13175–13193, doi:10.1074/jbc.M115.712083.

66. Hatakeyama, S.; Matsumoto, M.; Kamura, T.; Murayama, M.; Chui, D.H.; Planel, E.; Takahashi, R.; Nakayama, K.I.; Takashima, A. U-box protein carboxyl terminus of Hsc70-interacting protein (CHIP) mediates polyubiquitylation preferentially on four-repeat Tau and is involved in neurodegeneration of tauopathy. *J. Neurochem.* 2004, 91, 299–307, doi:10.1111/j.1471-4159.2004.02713.x.

67. Demisheit, A.; Fraiberg, M.; Berko, D.; Tiross, B.; Elazar, Z.; Navon, A. SQSTM1/p62-mediated autophagy compensates for loss of proteasome polyubiquitin recruiting capacity. *Autophagy* 2017, 13, 1697–1708, doi:10.1080/15548627.2017.1356549.
68. Guthrie, C.R.; Kraemer, B.C. Proteasome inhibition drives HDAC6-dependent recruitment of tau to aggresomes. J. Mol. Neurosci. 2011, 45, 32–41, doi:10.1007/s12031-011-9502-x.

69. Leyk, J.; Goldbaum, O.; Noack, M.; Richter-Landsberg, C. Inhibition of HDAC6 modifies tau inclusion body formation and impairs autophagic clearance. J. Mol. Neurosci. 2015, 55, 1031–1046, doi:10.1007/s12031-014-0460-y.

70. Balmik, A.A.; Sonawane, S.K.; Chinnathambi, S. Modulation of Actin network and Tau phosphorylation by HDAC6 ZnF UBP domain. BioRxiv 2019, 702571, doi:10.1101/702571.

71. Bishop, P.; Rocca, D.; Henley, J.M. Ubiquitin C-terminal hydrolase L1 (UCH-L1): Structure, distribution and roles in brain function and dysfunction. Biochem. J. 2016, 473, 2453–2462, doi:10.1042/bcj20160082.

72. Xie, M.; Han, Y.; Yu, Q.; Wang, X.; Wang, S.; Liao, X. UCH-L1 Inhibition Decreases the Microtubule-Binding Function of Tau Protein. J. Alzheimers Dis. 2016, 49, 353–363, doi:10.3233/JAD-150032.

73. Yu, Q.; Zhang, H.; Li, Y.; Liu, C.; Wang, S.; Liao, X. UCH-L1 Inhibition Suppresses tau Aggresome Formation during Proteasomal Impairment. Mol. Neurobiol. 2017, 55, 3812–3821, doi:10.1007/s12035-017-0558-7.

74. Cohen, L.D.; Ziv, N.E. Recent insights on principles of synaptic protein degradation. F1000Res. 2017, 6, 675, doi:10.12688/f1000research.10599.1.

75. Marsh, J.; Alifragis, P. Synaptic dysfunction in Alzheimer’s disease: The effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention. Neuro Regen. Res. 2018, 13, 616–623, doi:10.4103/1673-5374.230276.

76. Zhao, X.L.; Wang, W.A.; Tan, J.X.; Huang, J.K.; Zhang, X.; Zhang, B.Z.; Wang, Y.H.; YangCheng, H.Y.; Zhu, H.L.; Sun, X.J., et al. Expression of beta-amyloid induced age-dependent presynaptic and axonal changes in Drosophila. J. Neurosci. 2010, 30, 1512–1522, doi:10.1523/jneurosci.3699-09.2010.

77. Kim, J.; Choi, I.Y.; Michaelis, M.L.; Lee, P. Quantitative in vivo measurement of early axonal transport deficits in a triple transgenic mouse model of Alzheimer’s disease using manganese-enhanced MRI. Neuroimage 2011, 56, 1286–1292, doi:10.1016/j.neuroimage.2011.02.039.

78. Gilley, J.; Seereeram, A.; Ando, K.; Mosely, S.; Andrews, S.; Kerschensteiner, M.; Misgeld, T.; Brion, J.P.; Anderton, B.; Hanger, D.P., et al. Age-dependent axonal transport and locomotor changes and tau hypophosphorylation in a “P301L” tau knockin mouse. Neurobiol. Aging. 2012, 33, e621, doi:10.1016/j.neurobiolaging.2011.02.014.

79. Hares, K.; Wilkins, A. Axonal transport proteins as biomarkers of neurodegeneration? Biomark. Med. 2017, 11, 589–591, doi:10.2217/bmm-2017-0163.

80. Wong, E.S.P.; Tan, J.M.M.; Soong, W.-E.; Hussein, K.; Nukina, N.; Dawson, V.L.; Dawson, T.M.; Cuervo, A.M.; Lim, K.-L. Autophagy-mediated clearance of aggresomes is not a universal phenomenon. Hum. Mol. Genet. 2008, 17, 2570–2582, doi:10.1093/hmg/ddn157.

81. Kanaan, N.M.; Morfini, G.A.; LaPointe, N.E.; Pigino, G.F.; Patterson, K.R.; Song, Y.; Andreadis, A.; Fu, Y.; Brady, S.T.; Binder, L.I. Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. J. Neurosci. 2011, 31, 9858–9868, doi:10.1523/jneurosci.0560-11.2011.

82. LaPointe, N.E.; Morfini, G.; Pigino, G.; Gaisina, I.N.; Kozikowski, A.P.; Binder, L.I.; Brady, S.T. The amino terminus of tau inhibits kinesin-dependent axonal transport: Implications for filament toxicity. J. Neurosci. Res. 2009, 87, 440–451, doi:10.1002/jnr.21850.

83. Pigino, G.; Morfini, G.; Atagi, Y.; Deshpande, A.; Yu, C.; Jungbauer, L.; LaDu, M.; Busciglio, J.; Brady, S. Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta. Proc. Natl. Acad. Sci. 2009, 106, 5907–5912, doi:10.1073/pnas.0901229106.

84. Dolma, K.; Iacobucci, G.J.; Hong Zheng, K.; Shandilya, J.; Toska, E.; White, J.A., 2nd; Spina, E.; Gunawardena, S. Presenilin influences glycosyn synthase kinase-3 beta (GSK-3beta) for kinesin-1 and dynein function during axonal transport. Hum. Mol. Genet. 2014, 23, 1121–1133, doi:10.1093/hmg/ddt505.

85. Kanaan, N.M.; Pigino, G.F.; Brady, S.T.; Lazarov, O.; Binder, L.I.; Morfini, G.A. Axonal degeneration in Alzheimer’s disease: When signaling abnormalities meet the axonal transport system. Exp. Neurol. 2013, 246, 44–53, doi:10.1016/j.expneurol.2012.06.003.

86. Tamminen, P.; Cai, Q. Defective retrograde transport impairs autophagic clearance in Alzheimer disease neurons. Autophagy 2017, 13, 982–984, doi:10.1080/15548627.2017.1291114.
87. Aboud, O.; Parcon, P.A.; DeWall, K.M.; Liu, L.; Mrak, R.E.; Griffin, W.S. Aging, Alzheimer's, and APOE genotype influence the expression and neuronal distribution patterns of microtubule motor protein dynactin-P50. Front. Cell Neurosci. 2015, 9, 103, doi:10.3389/fncel.2015.00103.

88. Stokin, G.B.; Lillo, C.; Falzone, T.L.; Brusch, R.G.; Rockenstein, E.; Mount, S.L.; Raman, R.; Davies, P.; Maslia, E.; Williams, D.S., et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 2005, 307, 1282–1288, doi:10.1126/science.1105681.

89. Funderburk, S.F.; Marcellino, B.K.; Yue, Z. Cell "self-eating" (autophagy) mechanism in Alzheimer's disease. Mi. Sinai J. Med. 2010, 77, 59–68, doi:10.1002/mj.20161.

90. Wu, H.Y.; Kuo, P.C.; Wang, Y.T.; Lin, H.T.; Roe, A.D.; Wang, B.Y.; Han, C.L.; Hyman, B.T.; Chen, Y.J.; Tai, H.C. beta-Amyloid Induces Pathology-Related Patterns of Tau Hyperphosphorylation at Synaptic Terminals. J. Neuropathol. Exp. Neurol. 2018, 77, 814–826, doi:10.1093/jnen/nyx059.

91. Viana da Silva, S.; Haberl, M.G.; Zhang, P.; Bethge, P.; Lemos, C.; Goncalves, N.; Gorlewicz, A.; Malezieux, M.; Goncalves, F.Q.; Grosjean, N., et al. Early synaptic deficits in the APP/PS1 mouse model of Alzheimer's disease involve neuronal adenosine A2A receptors. Nat. Commun. 2016, 7, 11915, doi:10.1038/ncomms11915.

92. Morfini, G.; Sebenyi, G.; Brown, H.; Pant, H.C.; Pigino, G.; DeBoer, S.; Beffert, U.; Brady, S.T. A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons. EMBO J. 2004, 23, 2235–2245, doi:10.1038/sj.emboj.7600237.

93. Pigino, G.; Morfini, G.; Pelsman, A.; Mattson, M.P.; Brady, S.T.; Busciglio, J. Alzheimer's presenilin 1 mutations impair kinesin-axonal transport. J. Neurosci. 2003, 23, 4499–4508.

94. Kanaan, N.M.; Morfini, G.; Pigino, G.; LaPointe, N.E.; Andreadis, A.; Song, Y.; Leitman, E.; Binder, L.I.; Brady, S.T. Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport. Neurobiol. Aging 2012, 33, 826 e815-830, doi:10.1016/j.neurobiolaging.2011.06.006.

95. Gowrishankar, S.; Wu, Y.; Ferguson, S.M. Impaired JIP3-dependent axonal lysosome transport promotes amyloid plaque pathology. J. Cell Biol. 2017, 216, 3291–3305, doi:10.1083/jcb.201612148.

96. Feng, T.; Tammineni, P.; Agrawal, C.; Jeong, Y.Y.; Cai, Q. Autophagy-mediated Regulation of BACE1 Protein Trafficking and Degradation. J. Biol. Chem. 2017, 292, 1679–1690, doi:10.1074/jbc.M116.766584.

97. Yang, C.; Cai, C.Z.; Song, J.X.; Tan, J.Q.; Durairajan, S.S.K.; Iyaswamy, A.; Wu, M.Y.; Chen, L.L.; Yue, Z.; Li, M., et al. NRBF2 is involved in the autophagic degradation process of APP-CTFs in Alzheimer disease models. Autophagy 2017, 13, 2028–2040, doi:10.1080/15548627.2017.1379633.

98. Nixon, R.A. Autophagy, amyloidogenesis and Alzheimer disease. J. Cell Sci. 2007, 120, 4081–4091, doi:10.1242/jcs.019265.

99. Chakraborty, D.; Felzen, V.; Hiebel, C.; Sturner, E.; Perumal, N.; Manicam, C.; Sehn, E.; Grus, F.; Wolfrum, U.; Behl, C. Enhanced autophagic-lysosomal activity and increased BAG3-mediated selective macroautophagy as adaptive response of neuronal cells to chronic oxidative stress. Redox Biol. 2019, 24, 101181, doi:10.1016/j.redox.2019.101181.

100. Tang, M.; Ji, C.; Pallo, S.; Rahman, I.; Johnson, G.V.W. Nrf2 mediates the expression of BAG3 and autophagy cargo adaptor proteins and tau clearance in an age-dependent manner. Neurobiol. Aging 2018, 63, 128–139, doi:10.1016/j.neurobiolaging.2017.12.001.

101. Wang, Q.; Li, J.; Yang, X.; Sun, H.; Gao, S.; Zhu, H.; Wu, J.; Jin, W. Nrf2 is associated with the regulation of basal transcription activity of the BRC1 gene. Acta Biochim. Biophys. Sin. (Shanghai) 2013, 45, 179–187, doi:10.1093/abbr/gmt001.

102. Dimitrov, S.; Brennerova, M.; Forejt, J. Expression profiles and intergenic structure of head-to-head oriented Brc1a and Nbr1 genes. Gene 2001, 262, 89–98, doi:10.1016/s0378-1119(00)00549-7.

103. Kirklin, V.; Lamark, T.; Sou, Y.S.; Bjorkoy, G.; Nunn, J.L.; Bruun, J.A.; Shvets, E.; MeEwan, D.G.; Clausen, T.H.; Wild, P., et al. A role for NBR1 in autophagosomal degradation of ubiquitinated substrates. Mol. Cell 2009, 33, 505–516, doi:10.1016/j.molcel.2009.01.020.

104. Kanninen, K.; Malm, T.M.; Jyrkkakanen, H.K.; Goldsteins, G.; Keksa-Goldsteine, V.; Tanila, H.; Yamamoto, M.; Yla-Herttuala, S.; Levonen, A.L.; Koistinaho, J. Nuclear factor erythroid 2-related factor 2 protects against beta amyloid. Mol. Cell Neurosci. 2008, 39, 302–313, doi:10.1016/j.mcn.2008.07.010.

105. Jena, K.K.; Kolapalli, S.P.; Mehta, S.; Nath, P.; Das, B.; Sahoo, P.K.; Ahad, A.; Syed, G.H.; Raghav, S.K.; Senapati, S., et al. TRIM16 controls assembly and degradation of protein aggregates by modulating the p62-NRF2 axis and autophagy. EMBO J. 2018, 37, doi:10.15252/emboj.201798358.
106. Komatsu, M.; Kurokawa, H.; Waguri, S.; Taguchi, K.; Kobayashi, A.; Ichimura, Y.; Sou, Y.S.; Ueno, I.; Sakamoto, A.; Tong, K.I., et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. *Nat. Cell Biol.* **2010**, *12*, 213–223, doi:10.1038/nclb2021.

107. Taguchi, K.; Fujikawa, N.; Komatsu, M.; Ishii, T.; Urno, M.; Akaike, T.; Motohashi, H.; Yamamoto, M. Keap1 degradation by autophagy for the maintenance of redox homeostasis. *Proc. Natl. Acad. Sci.* **2012**, *109*, 13561–13566, doi:10.1073/pnas.1121572109.

108. Tanji, K.; Miki, Y.; Ozaki, T.; Murayama, A.; Yoshida, H.; Mimura, J.; Matsumiya, T.; Mori, F.; Imaizumi, T.; Itoh, K., et al. Phosphorylation of serine 349 of p62 in Alzheimer’s disease brain. *Acta Neuropathol. Commun.* **2014**, *2*, 50, doi:10.1186/2051-5960-2-50.

109. Nicot, A.S.; Lo Verso, F.; Ratti, F.; Pilot-Storck, F.; Streichenberger, N.; Sandri, M.; Schaeffer, L.; Goiollot, E. Phosphorylation of NBR1 by GSK3 modulates protein aggregation. *Autophagy* **2014**, *10*, 1036–1053, doi:10.4161/auto.28479.

110. Leroy, K.; Yilmaz, Z.; Brion, J.P. Increased level of active GSK-3beta in Alzheimer’s disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. *Neuropathol. Appl. Neurobiol.* **2007**, *33*, 43–55, doi:10.1111/j.1365-2990.2006.00795.x.

111. Odagiri, S.; Tanji, K.; Mori, F.; Miki, Y.; Kakita, A.; Takahashi, H.; Wakabayashi, K. Brain expression level and activity of HDAC6 protein in neurodegenerative dementia. *Biochem. Biophys. Res. Commun.* **2013**, *430*, 394–399, doi:10.1016/j.bbrc.2012.11.034.

112. Govindarajan, N.; Rao, P.; Burkhardt, S.; Sananbenesi, F.; Schluter, O.M.; Bradke, F.; Lu, J.; Fischer, A. Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer’s disease. *EMBO Mol. Med.* **2013**, *5*, 52–63, doi:10.1002/emmm.201201923.

113. Tseng, J.H.; Xie, L.; Song, S.; Xie, Y.; Allen, L.; Ajit, D.; Hong, J.S.; Chen, X.; Meeker, R.B.; Cohen, T.J. The Deacetylase HDAC6 Mediates Endogenous Neuritic Tau Pathology. *Cell Rep.* **2017**, *20*, 2169–2183, doi:10.1016/j.celrep.2017.07.082.

114. Fan, S.J.; Huang, F.I.; Liou, J.P.; Yang, C.R. The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model. *Cell Death Dis.* **2018**, *9*, 655, doi:10.1038/s41419-018-0688-5.

115. Sahara, N.; Murayama, M.; Mizoroki, T.; Urushitani, M.; Imai, Y.; Takahashi, R.; Murata, S.; Tanaka, K.; Takashima, A. In vivo evidence of CHIP up-regulation attenuating tau aggregation. *J. Neurochem.* **2005**, *94*, 1254–1263, doi:10.1111/j.1471-4159.2005.03272.x.

116. Caccamo, A.; Ferreira, E.; Branca, C.; Oddo, S. p62 improves AD-like pathology by increasing autophagy. *Mol. Psychiatry* **2017**, *22*, 865–873, doi:10.1038/mp.2016.139.

117. Ramesh Babu, J.; Lamar Seibenhener, M.; Peng, J.; Strom, A.L.; Kemppainen, R.; Cox, N.; Zhu, H.; Wooten, M.C.; Diaz-Meco, M.T.; Moscat, J., et al. Genetic inactivation of p62 leads to accumulation of hyperphosphorylated tau and neurodegeneration. *J. Neurochem.* **2008**, *106*, 107–120, doi:10.1111/j.1471-4199.2008.05340.x.

118. Joshi, G.; Gan, K.A.; Johnson, D.A.; Johnson, J.A. Increased Alzheimer’s disease-like pathology in the APP/PS1DeltaE9 mouse model lacking Nrf2 through modulation of autophagy. *Neurobiol. Aging* **2015**, *36*, 664–679, doi:10.1016/j.neurobiolaging.2014.09.004.

119. Aviles-Reyes, R.X.; Jonhson, D.; Johnson, J. Astrocytic Overexpression of Nrf2 Leads to Reduced Disease Progression in App/PS1 Transgenic Mice. *Alzheimer’s Dement.* **2018**, *14*, P346–P347, doi:10.1016/j.jalz.2018.06.182.

120. Jo, C.; Gundemir, S.; Pritchard, S.; Jin, Y.N.; Rahman, I.; Johnson, G.V. Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52. *Nat. Commun.* **2014**, *5*, 3496, doi:10.1038/ncomms4496.

121. Roczniak-Ferguson, A.; Petit, C.S.; Froehlich, F.; Qian, S.; Ky, J.; Angarola, B.; Walther, T.C.; Ferguson, S.M. The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. *Sci. Signal.* **2012**, *5*, ra42, doi:10.1126/scisignal.2002790.

122. Wang, H.; Wang, R.; Carrera, I.; Xu, S.; Lakshmana, M.K. TFEB Overexpression in the P301S Model of Tauopathy Mitigates Increased PHF1 Levels and Lipofuscin Puncta and Rescues Memory Deficits. *eNeuro* **2016**, *3*, doi:10.1523/ENEURO.0042-16.2016
123. Polito, V.A.; Li, H.; Martini-Stoica, H.; Wang, B.; Yang, L.; Xu, Y.; Swatzlander, D.B.; Palmieri, M.; di Ronza, A.; Lee, V.M.Y., et al. Selective clearance of aberrant tau proteins and rescue of neurotoxicity by transcription factor EB. *EMBO Mol. Med.* **2014**, *6*, 1142–1160, doi:10.15252/emmm.201303671.

124. Xiao, Q.; Yan, P.; Ma, X.; Liu, H.; Perez, R.; Zhu, A.; Gonzales, E.; Tripoli, D.L.; Czerniewski, L.; Ballabio, A., et al. Neuronal-Targeted TFEB Accelerates Lysosomal Degradation of APP, Reducing Aβ Generation and Amyloid Plaque Pathogenesis. *J. Neurosci.* **2015**, *35*, 12137–12151.

125. Napolitano, G.; Ballabio, A. TFEB at a glance. *J. Cell Sci.* **2016**, *129*, 2475–2481, doi:10.1242/jcs.146365.

126. Sardiello, M. Transcription factor EB: From master coordinator of lysosomal pathways to candidate therapeutic target in degenerative storage diseases. *Ann. N. Y. Acad. Sci.* **2016**, *1371*, 3–14, doi:10.1111/nyas.13131.

127. Tsunemi, T.; Ashe, T.D.; Morrison, B.E.; Soriano, K.R.; Au, J.; Roque, R.A.; Lazarowski, E.R.; Damian, V.A.; Masliyah, E.; La Spada, A.R. PGC-1alpha rescues Huntington’s disease proteotoxicity by preventing oxidative stress and promoting TFEB function. *Sci. Transl. Med.* **2012**, *4*, 142ra197, doi:10.1126/scitranslmed.3003799.

128. Luo, R.; Su, L.Y.; Li, G.; Yang, J.; Liu, Q.; Yang, L.X.; Zhang, D.F.; Zhou, H.; Xu, M.; Fan, Y., et al. Activation of PPARG-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model. *Autophagy* **2019**, *15*, 1–18, doi:10.1080/15548627.2019.1596488.

129. Sweeney, G.; Song, J. The association between PGC-1alpha and Alzheimer’s disease. *Anat. Cell Biol.* **2016**, *49*, 1–6, doi:10.5115/acb.2016.49.1.1.

130. Song, J.X.; Sun, Y.R.; Peluso, I.; Zeng, Y.; Yu, X.; Lu, J.H.; Xu, Z.; Wang, M.Z.; Liu, L.F.; Huang, Y.Y., et al. A novel curcumin analog binds to and activates TFEB in vitro and in vivo independent of MTOR inhibition. *Autophagy* **2016**, *12*, 1372–1389, doi:10.1080/15548627.2016.1179404.

131. Song, J.X.; Malampati, S.; Zeng, Y.; Durairajan, S.S.K.; Yang, C.-B.; Tong, B.C.-K.; Iyaswamy, A.; Shang, W.-B.; Sreenivasmurthy, S.G.; Zhu, Z., et al. A small molecule transcription factor EB activator ameliorates beta-amyloid precursor protein and Tau pathology in Alzheimer’s disease models. *Aging Cell* **2019**, *e13069*, doi:10.1111/acel.13069.

132. Hara, T.; Nakamura, K.; Matsui, M.; Yamamoto, A.; Nakahara, Y.; Suzuki-Migishima, R.; Yokoyama, M.; Mishima, K.; Saito, I.; Okano, H., et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. *Nature* **2006**, *441*, 885–889, doi:10.1038/nature04724.

133. Xu, H.; Ren, D. Lysosomal physiology. *Annu. Rev. Physiol.* **2015**, *77*, 57–80, doi:10.1146/annurev-physiol-021014-071649.

134. Lee, J.H.; Yu, W.H.; Kumar, A.; Lee, S.; Mohan, P.S.; Peterhoff, C.M.; Wolfe, D.M.; Martinez-Vicente, M.; Massey, A.C.; Sovak, G., et al. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. *Cell* **2010**, *141*, 1146–1158, doi:10.1016/j.cell.2010.05.008.

135. Jiang, Y.; Sato, Y.; Im, E.; Berg, M.; Bordi, M.; Darji, S.; Kumar, A.; Mohan, P.S.; Bandyopadhyay, U.; Diaz, A., et al. Lysosomal Dysfunction in Down Syndrome Is APP-Dependent and Mediated by APP-betaCTF (C99). *J. Neurosci.* **2019**, *39*, 5255–5268, doi:10.1523/JNEUROSCI.0578-19.2019.

136. Lee, J.H.; McBrayer, M.K.; Wolfe, D.M.; Haslett, L.J.; Kumar, A.; Sato, Y.; Lie, P.P.; Mohan, P.; Coffey, E.E.; Kompella, U., et al. Presenilin 1 Maintains Lysosomal Ca(2+) Homeostasis via TRPML1 by Regulating vATPase-Mediated Lysosome Acidification. *Cell Rep.* **2015**, *12*, 1430–1444, doi:10.1016/j.celrep.2015.07.050.

137. Prevot, G.; Soria, F.N.; Thiolat, M.L.; Daniel, J.; Verlhac, J.B.; Blanchard-Desce, M.; Bezard, E.; Barthelemy, P.; Crauste-Manciet, S.; Dehay, B. Harnessing Lysosomal pH through PLGA Nanoemulsion as a Treatment of Lysosomal-Related Neurodegenerative Diseases. *Bioconjug. Chem.* **2018**, *29*, 4083–4089, doi:10.1021/acs.bioconjchem.8b00697.

138. Baltazar, G.C.; Guha, S.; Lu, W.; Lim, J.; Boesze-Battaglia, K.; Latties, A.M.; Tyagi, P.; Kompella, U.B.; Mitchell, C.H. Acidic nanoparticles are trafficked to lysosomes and restore an acidic lysosomal pH and degradative function to compromised ARPE-19 cells. *PLoS ONE* **2012**, *7*, e49635, doi:10.1371/journal.pone.0049635.

139. Mirzoev, T.; Tyganov, S.; Vilchinskaya, N.; Lomonosova, Y.; Shenkman, B. Key Markers of mTORC1-Dependent and mTORC1-Independent Signaling Pathways Regulating Protein Synthesis in Rat Soleus Muscle During Early Stages of Hindlimb Unloading. *Cell Physiol. Biochem.* **2016**, *39*, 1011–1020, doi:10.1159/000447808.

140. Kim, J.; Kundu, M.; Viollet, B.; Guan, K.L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. *Nat. Cell Biol.* **2011**, *13*, 132–141, doi:10.1038/ncb2152.
141. Shang, L.; Wang, X. AMPK and mTOR coordinate the regulation of Ulk1 and mammalian autophagy initiation. *Autophagy* 2011, 7, 924–926, doi:10.4161/auto.7.8.15860.

142. Rena, G.; Guo, S.; Cichy, S.C.; Unterman, T.G.; Cohen, P. Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. *J. Biol. Chem.* 1999, 274, 17179–17183, doi:10.1074/jbc.274.24.17179.

143. Gwinn, D.M.; Shackelford, D.B.; Egan, D.F.; Mihaylova, M.M.; Mery, A.; Vasquez, D.S.; Turk, B.E.; Shaw, R.J. AMPK phosphorylation of raptor mediates a metabolic checkpoint. *Mol. Cell* 2008, 30, 214–226, doi:10.1016/j.molcel.2008.03.003.

144. Spilman, P.; Podlutskaya, N.; Hart, M.J.; Debnath, J.; Gorostiza, O.; Bredesen, D.; Richardson, A.; Strong, R.; Galvan, V. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer’s disease. *PLoS ONE* 2010, 5, e9979, doi:10.1371/journal.pone.0009979.

145. Wu, Y.T.; Tan, H.L.; Shui, G.; Bautvy, C.; Huang, Q.; Wenk, M.R.; Ong, C.N.; Codogno, P.; Shen, H.M. Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. *J. Biol. Chem.* 2010, 285, 10850–10861, doi:10.1074/jbc.M109.080796.

146. Lin, A.L.; Zheng, W.; Halloran, J.J.; Burbank, R.R.; Hussong, S.A.; Hart, M.J.; Javors, M.; Shih, Y.Y.; Muir, E.; Solano Fonseca, R., et al. Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer’s disease. *J. Cereb. Blood Flow Metab.* 2013, 33, 1412–1421, doi:10.1038/jcbfm.2013.82.

147. Mizuno, T.; Fukuda, T.; Christians, U.; Perentesis, J.P.; Fouladi, M.; Vinks, A.A. Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: A report from the Children’s Oncology Group. *Br. J. Clin. Pharmacol.* 2017, 83, 1097–1107, doi:10.1111/bcp.13181.

148. Jiang, T.; Yu, J.T.; Zhu, X.C.; Zhang, Q.Q.; Cao, L.; Wang, H.F.; Tan, M.S.; Gao, Q.; Qin, H.; Zhang, Y.D., et al. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance. *Neuropharmacol.* 2014, 85, 121–130, doi:10.1016/j.neuropharm.2014.05.032.

149. Caccamo, A.; Magri, A.; Medina, D.X.; Wisely, E.V.; Lopez-Aranda, M.F.; Silva, A.J.; Oddo, S. mTOR regulates tau phosphorylation and degradation: Implications for Alzheimer’s disease and other tauopathies. *Aging Cell* 2013, 12, 370–380, doi:10.1111/acel.12057.

150. Wang, C.; Zhang, X.; Teng, Z.; Zhang, T.; Li, Y. Downregulation of PI3K/Akt/mTOR signaling pathway in curcumin-induced autophagy in APP/PS1 double transgenic mice. *Eur. J. Pharm.* 2014, 740, 312–320, doi:10.1016/j.ejphar.2014.06.051.

151. Begum, A.N.; Jones, M.R.; Lim, G.P.; Morihiara, T.; Kim, P.; Heath, D.D.; Rock, C.L.; Pruitt, M.A.; Yang, F.; Hudspeth, B., et al. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer’s disease. *J. Pharm. Exp. Ther.* 2008, 326, 196–208, doi:10.1124/jpet.107.137455.

152. Garcia-Alloza, M.; Borrelli, L.A.; Rozkalne, A.; Hyman, B.T.; Bacsai, B.J. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. *J. Neurochem.* 2007, 102, 1095–1104, doi:10.1111/j.1471-4159.2007.04613.x.

153. Yang, F.; Lim, G.P.; Begum, A.N.; Ubeda, O.J.; Simmons, M.R.; Ambegaokar, S.S.; Chen, P.P.; Kayed, R.; Glabe, C.G.; Frautschy, S.A., et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. *J. Biol. Chem.* 2005, 280, 5892–5901, doi:10.1074/jbc.M404751200.

154. Pan, R.; Qiu, S.; Lu, D.X.; Dong, J. Curcumin improves learning and memory ability and its neuroprotective mechanism in mice. *Chin. Med. J.* 2008, 121, 832–839.

155. Beevers, C.S.; Chen, L.; Liu, L.; Luo, Y.; Webster, N.J.; Huang, S. Curcumin disrupts the Mammalian target of rapamycin-raptor complex. *Cancer Res.* 2009, 69, 1000–1008, doi:10.1158/0008-5472.can-08-2367.

156. Goel, A.; Kunnumakkara, A.B.; Aggarwal, B.B. Curcumin as "Curcumin": From kitchen to clinic. *Biochem. Pharm.* 2008, 75, 787–809, doi:10.1016/j.bcp.2007.08.016.

157. Darvesh, A.S.; Carroll, R.T.; Bishayee, A.; Novotny, N.A.; Geldenhuys, W.J.; Van der Schyf, C.J. Curcumin and neurodegenerative diseases: A perspective. *Expert Opin. Investig. Drugs* 2012, 21, 1123–1140, doi:10.1517/13543784.2012.693479.

158. Rigacci, S.; Miceli, C.; Nediani, C.; Berti, A.; Cascella, R.; Pantano, D.; Nardiello, P.; Luccarini, I.; Casamenti, F.; Stefani, M. Oleuropein aglycone induces autophagy via the AMPK/mTOR signalling pathway: A mechanistic insight. *Oncotarget* 2015, 6, 35344–35357, doi:10.18632/oncotarget.6119.
159. Grossi, C.; Rigacci, S.; Ambrosini, S.; Ed Damí, T.; Luccioni, I.; Traini, C.; Failli, P.; Berti, A.; Casamenti, F.; Stefani, M. The polyphenol oleuropein aglycone protects TgCRND8 mice against Aβ plaque pathology. PLoS ONE 2013, 8, e71702, doi:10.1371/journal.pone.0071702.

160. Luccioni, I.; Grossi, C.; Rigacci, S.; Coppi, E.; Pugliese, A.M.; Pantano, D.; la Marca, G.; Ed Damí, T.; Berti, A.; Stefani, M., et al. Oleuropein aglycone protects against pyroglutamyalted-3 amyloid-β toxicity: Biochemical, epigenetic and functional correlates. Neurobiol. Aging 2015, 36, 648–663, doi:10.1016/j.neurobiolaging.2014.08.029.

161. Congdon, E.E.; Wu, J.W.; Myeku, N.; Figueroa, Y.H.; Herman, M.; Marinec, P.S.; Gestwicki, J.E.; Dickey, C.A.; Yu, W.H.; Duff, K.E. Methylthionium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy 2012, 8, 609–622, doi:10.4161/auto.19048.

162. Soeda, Y.; Saito, M.; Maeda, S.; Ishida, K.; Nakamura, A.; Kojima, S.; Takashima, A. Methylene Blue Inhibits Formation of Tau Fibrils but not of Granular Tau Oligomers: A Plausible Key to Understanding Failure of a Clinical Trial for Alzheimer’s Disease. J. Alzheimers Dis. 2019, 68, 1677–1686, doi:10.3233/jad-181001.

163. Settembre, C.; Di Malta, C.; Polito, V.A.; Garcia Arenčibia, M.; Vetrini, F.; Erdin, S.; Erdin, S.U.; Huyhn, T.; Medina, D.; Colella, P., et al. TFEB links autophagy to lysosomal biogenesis. Science 2011, 332, 1429–1433, doi:10.1126/science.1204592.

164. Xu, Y.; Ren, J.; He, X.; Chen, H.; Wei, T.; Feng, W. YWHA/14-3-3 proteins recognize phosphorylated TFEB by a noncanonical mode for controlling TFEB cytoplasmic localization. Autophagy 2019, 15, 1017–1030, doi:10.1080/15548627.2019.1569928.

165. Sardiello, M.; Palmieri, M.; di Ronza, A.; Medina, D.L.; Valenza, M.; Gennarino, V.A.; Di Malta, C.; Donaudy, F.; Embrione, V.; Polishchuk, R.S., et al. A gene network regulating lysosomal biogenesis and function. Science 2009, 325, 473–477, doi:10.1126/science.1174447.

166. Palmieri, M.; Impey, S.; Kang, H.; di Ronza, A.; Pelz, C.; Sardiello, M.; Ballabio, A. Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways. Hum. Mol. Genet. 2011, 20, 3852–3866, doi:10.1093/hmg/ddr306.

167. Settembre, C.; Zoncu, R.; Medina, D.L.; Vetrini, F.; Erdin, S.; Huyhn, T.; Ferron, M.; Karsenty, G.; Vellard, M.C.; Facchini, V., et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 2012, 31, 1095–1108, doi:10.1038/emboj.2012.32.

168. Medina, D.L.; Di Paola, S.; Peluso, I.; Armani, A.; De Stefani, D.; Venditti, R.; Montefusco, S.; Scotto-Rosato, A.; Prezioso, C.; Forrester, A., et al. Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB. Nat. Cell Biol. 2015, 17, 288–299, doi:10.1038/ncb3114.

169. Rusmini, P.; Cortese, K.; Crippa, V.; Cristofani, R.; Cicardi, M.E.; Ferrari, V.; Vezzoli, G.; Tedesco, B.; Meroni, M.; Messi, E., et al. Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration. Autophagy 2019, 15, 631–651, doi:10.1080/15548627.2018.1535292.

170. Schaeffer, V.; Lavenir, I.; Ozcelik, S.; Tolnay, M.; Winkler, D.T.; Goedert, M. Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain 2012, 135, 2169–2177, doi:10.1093/brain/aws143.

171. Kruger, U.; Wang, Y.; Kumar, S.; Mandelkow, E.M. Autophagic degradation of tau in primary neurons and its enhancement by trehalose. Neurobiol. Aging 2012, 33, 2291–2305, doi:10.1016/j.neurobiolaging.2011.11.009.

172. Tien, N.T.; Karaca, I.; Tamboli, I.Y.; Walter, J. Trehalose Alters Subcellular Trafficking and the Metabolism of the Alzheimer-associated Amyloid Precursor Protein. J. Biol. Chem. 2016, 291, 10528–10540, doi:10.1074/jbc.M116.719286.

173. Portbury, S.D.; Hare, D.J.; Sgambelloni, C.; Perronnes, K.; Portbury, A.J.; Finkelstein, D.I.; Adlard, P.A. Trehalose Improves Cognition in the Transgenic Tg2576 Mouse Model of Alzheimer’s Disease. J. Alzheimers Dis. 2017, 60, 549–560, doi:10.3233/jad-170322.

174. Du, J.; Liang, Y.; Xu, F.; Sun, B.; Wang, Z. Trehalose rescues Alzheimer’s disease phenotypes in APP/PS1 transgenic mice. J. Pharm. Pharm. 2013, 65, 1753–1756, doi:10.1111/jfph.12108.

175. Bagrov, A.Y.; Shapiro, J.L.; Fedorova, O.V. Endogenous cardiotonic steroids: Physiology, pharmacology, and novel therapeutic targets. Pharm. Rev. 2009, 61, 9–38, doi:10.1124/pr.108.007711.

176. Song, H.L.; Demirev, A.V.; Kim, N.Y.; Kim, D.H.; Yoon, S.Y. Ouabain activates transcription factor EB and exerts neuroprotection in models of Alzheimer’s disease. Mol. Cell Neurosci. 2019, 95, 13–24, doi:10.1016/j.mcn.2018.12.007.
177. Li, Y.; Xu, M.; Ding, X.; Yan, C.; Song, Z.; Chen, L.; Huang, X.; Wang, X.; Jian, Y.; Tang, G., et al. Protein kinase C controls lysosome biogenesis independently of mTORC1. *Nat. Cell Biol.* **2016**, *18*, 1065–1077, doi:10.1038/ncb3407.

178. Chandra, S.; Roy, A.; Jana, M.; Pahan, K. Cinnamic acid activates PPARalpha to stimulate lysosomal biogenesis and lower Amyloid plaque pathology in an Alzheimer’s disease mouse model. *Neurobiol. Dis.* **2019**, *124*, 379–395, doi:10.1016/j.nbd.2018.12.007.

179. Chandra, S.; Jana, M.; Pahan, K. Aspirin Induces Lysosomal Biogenesis and Attenuates Amyloid Plaque Pathology in a Mouse Model of Alzheimer’s Disease via PPARalpha. *J. Neurosci.* **2018**, *38*, 6682–6699, doi:10.1523/jneurosci.0054-18.2018.

180. Ozcelik, S.; Fraser, G.; Castets, P.; Schaeffer, V.; Skachokova, Z.; Breu, K.; Clavaguera, F.; Sinnreich, M.; Kappos, L.; Goedert, M., et al. Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice. *PLoS ONE* **2013**, *8*, e62459, doi:10.1371/journal.pone.0062459.

181. Frederick, C.; Ando, K.; Leroy, K.; Heraud, C.; Suain, V.; Buee, L.; Brion, J.P. Rapamycin ester analog CCI-779/Temsirolimus alleviates tau pathology and improves motor deficit in mutant tau transgenic mice. *J. Alzheimers Dis.* **2015**, *44*, 1145–1156, doi:10.3233/JAD-142097.

182. Wang, C.M.; Liu, M.Y.; Wang, F.; Wei, M.J.; Wang, S.; Wu, C.F.; Yang, J.Y. Anti-amnesic effect of pseudoginsenoside-F11 in two mouse models of Alzheimer’s disease. *Pharm. Biochem. Behav.* **2013**, *106*, 57–67, doi:10.1016/j.pbb.2013.03.010.

183. Zhang, Z.; Yang, J.; Liu, C.; Xie, J.; Qiu, S.; Yang, X.; Wu, C. Pseudoginsenoside-F11 alleviates cognitive deficits and Alzheimer’s disease-type pathologies in SAMP8 mice. *Pharm. Res.* **2019**, *139*, 512–523, doi:10.1007/s11095-018-2259-y.

184. Penney, J.; Ralvenius, W.T.; Tsai, L.H. Modeling Alzheimer’s disease with iPSC-derived brain cells. *Mol. Psychiatry* **2019**, *25*, 148–167, doi:10.1038/s41380-019-0468-3.

185. Neff, E.P. Animal models of Alzheimer’s disease embrace diversity. *Lab. Anim.* **2019**, *48*, 255–259, doi:10.1017/s1479164184599-0377-8.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).